These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8259544)

  • 1. Evaluation of factor VIII deficient plasmas.
    Barrowcliffe TW; Tubbs JE; Wong MY
    Thromb Haemost; 1993 Sep; 70(3):433-7. PubMed ID: 8259544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
    Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T
    Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
    Barrowcliffe TW; Raut S; Sands D; Hubbard AR
    Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assay discrepancies with highly purified factor VIII concentrates.
    Dawson NJ; Kemball-Cook G; Barrowcliffe TW
    Haemostasis; 1989; 19(3):131-7. PubMed ID: 2501185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of Factor VIII-IV. Establishment of the 3rd International Standard for Factor VIII: C concentrate.
    Barrowcliffe TW; Curtis AD; Thomas DP
    Thromb Haemost; 1983 Oct; 50(3):697-702. PubMed ID: 6417819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
    Kang HN; Kim SN; Lee SH; Hong SH
    Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization of assays of factor VIII and factor IX.
    Barrowcliffe TW
    Ric Clin Lab; 1990; 20(2):155-65. PubMed ID: 2115197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods.
    Nilsson IM; Kirkwood TB; Barrowcliffe TW
    Thromb Haemost; 1979 Dec; 42(4):1230-9. PubMed ID: 120619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of phospholipid reagents used in coagulation I: some general properties and their sensitivity to factor VIII.
    Barrowcliffe TW; Gray E
    Thromb Haemost; 1981 Oct; 46(3):629-33. PubMed ID: 6797093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
    Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
    Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
    Kessler CM; Bernstein Z; Ghesani S; Shamsipour Z; Frances C; Zucker ML; LaDuca FM
    Am J Hematol; 1996 Mar; 51(3):181-5. PubMed ID: 8619397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay.
    Nougier C; Sobas F; Nguyen TK; Carage ML; Lienhart A; Négrier C
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):151-4. PubMed ID: 21192255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multicenter study on purified protein C concentrates and defined plasma levels].
    Regnault V; Houbouyan L; Michalski C; Vergnes C; Briquel ME; Droulle C; Delattre H; Boisseau M; Alexandre P; Poltron G
    Ann Biol Clin (Paris); 1991; 49(6):345-50. PubMed ID: 1759729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardization of factor IX: standards for "purified" factor IX concentrates.
    Lamb MA; Fricke WA; Rastogi SC
    Thromb Haemost; 1991 Nov; 66(5):548-51. PubMed ID: 1803618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automation of two-stage factor VIII assay.
    Stirling Y; Howarth DJ; Vickers M; North WR; Meade TW
    Thromb Haemost; 1978 Apr; 39(2):455-65. PubMed ID: 580993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyophilised plasmas for one-stage determination of factor VIII.
    Sikorová J; Vorlová Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):906-13. PubMed ID: 6162757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
    Molina Alejandro R; Lorenzo Herrero JI; Haya Guaita S; Querol Fuentes F; Aznar Lucea JA
    Rev Clin Esp; 1996 Jun; 196(6):365-9. PubMed ID: 8767071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.